Performance Evaluation of In Vitro Diagnostic Reagents for Mycobacterium tuberculosis and Non-tuberculous Mycobacteria by FDA Approval
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Tuberculosis (TB) is a bacterial infection disease caused by members of the species Mycobacterium tuberculosis (MTB) complex. Approximately one third of the world's population is infected with TB. In Korea, approximately 40,000 new patients are identified each year. Moreover, infections from non-tuberculous mycobacteria (NTM) have also increased. In the diagnosis of TB and NTM, traditional bacterial cultures are required for 3 to 4 weeks. Therefore, rapid and accurate diagnostic tests for TB and NTM are needed. To distinguish between TB and NTM, a range of diagnostic methods have been developed worldwide. In vitro diagnostic assays are constantly being developed to meet the increasing need for the rapid and accurate identification for TB and NTM. On the other hand, the performance evaluations of in vitro diagnostic reagents for TB and NTM are lacking. Recently, the Korea Food and Drug Administration (KFDA) issued a guideline for in vitro diagnostic reagents for MTB and NTM. Here, this study analyzed the performance of currently developed in vitro diagnostic reagents for TB and NTM in the US FDA. This analysis of US FDA approved molecular assays could serve as a useful reference for an evaluation of the reagent performance of TB and NTM.
Abstract
Tuberculosis (TB) is a bacterial infection disease caused by members of the species Mycobacterium tuberculosis (MTB) complex. Approximately one third of the world's population is infected with TB. In Korea, approximately 40,000 new patients are identified each year. Moreover, infections from non-tuberculous mycobacteria (NTM) have also increased. In the diagnosis of TB and NTM, traditional bacterial cultures are required for 3 to 4 weeks. Therefore, rapid and accurate diagnostic tests for TB and NTM are needed. To distinguish between TB and NTM, a range of diagnostic methods have been developed worldwide. In vitro diagnostic assays are constantly being developed to meet the increasing need for the rapid and accurate identification for TB and NTM. On the other hand, the performance evaluations of in vitro diagnostic reagents for TB and NTM are lacking. Recently, the Korea Food and Drug Administration (KFDA) issued a guideline for in vitro diagnostic reagents for MTB and NTM. Here, this study analyzed the performance of currently developed in vitro diagnostic reagents for TB and NTM in the US FDA. This analysis of US FDA approved molecular assays could serve as a useful reference for an evaluation of the reagent performance of TB and NTM.
참고문헌 (40)
- Global tuberculosis report 2017, "WHO", WHO institute, ~ (2017)
- Prevots DR, "Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs", Eur Respir J, 49(4) (2017)
- Microbiology device, reclassification of nucleic acid-based systems for Mycobacterium tuberculosis complex, "Food and Drug Administration", Department of Health and Human Service, ~ (2013)
- Microbiology device. Class II special controls guideline: nucleic acid-based in vitro diagnostic devices for the detection of Mycobacterium tuberculosis complex in respiratory specimens, "Food and Drug Administration", Department of Health and Human Service, ~ (2014)
- Microbiology Device. Class II special controls guideline: nucleic acid-based in vitro diagnostic devices for the detection of Mycobacterium tuberculosis complex and genetic mutations associated with Mycobacterium tuberculosis complex antibiotic resistance in respiratory specimens, "Food and Drug Administration", Department of Health and Human Service, ~ (2014)
- Non-tuberculous Mycobacterial lung infection public meeting. The voice of the patient, "Food and Drug Administration", Department of Health and Human Service, ~ (2016)
- Griffith DE, "An official ATS", IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases, 2007, pp.175(4), 367~416
- Joint committee for the revision of Korean guidelines for Tuberculosis Korea centers for disease control and Prevention, "Korean guidelines for Tuberculosis 2nd edition", 1~270 (2014)
- "Target amplification test for the direct detection of Mycobacterium tuberculosis. Summary of safety and effectiveness data", ~ (1999)
- TEX> Mycobacterium Tuberculosis test, "Premarket approval of Roche molecular systems <TEX>$AMPLICOR^{(R)}$<", pp.1996, Kimber Richter
- 510(k). K131706, "Food and Drug Administration", Department of Health and Human Service, ~ (2013)
- Huang H, "Rifampicin resistance and multidrug-resistant Tuberculosis detection using Xpert MTB", RIF in Wuhan, China: a retrospective study, 2017, ~
- Sanne CVK, "Effect of introducing Xpert MTB", RIF to test and treat Individuals at risk of multidrug- resistant Tuberculosis in Kazakhstan: A prospective cohort study, 2015, pp.10(8), e0136368~
- Geleta DA, "Xpert MTB", RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility, 2015, pp.15, 220~
- Detjen AK, "Xpert MTB", RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis, 2015, pp.3(6), 451~461
- Antonenka U, "Comparison of Xpert MTB", RIF with ProbeTec ET DTB and COBAS TaqMan MTB for direct detection of M. tuberculosis complex in respiratory specimens, 2013, pp.20(13), 280~
- Chen X, "Real-time PCR and amplified <TEX>$MTD^{(R)}$<", TEX> for rapid detection of Mycobacterium tuberculosis in pulmonary specimens, 2012, pp.16(2), 235~239
- Papaventsis D, "Impact of the Gen-Probe Amplified <TEX>$MTD^{(R)}$<", TEX> Test on tuberculosis diagnosis in children, 2012, pp.16(3), 384~390
- Guerra RL, "Use of the amplified Mycobacterium tuberculosis direct test in a public health laboratory: test performance and impact on clinical care", Chest, 132(3), pp.946~951 (2007)[DOI]
- David WD, "Cost-effectiveness analysis of the Gen-Probe amplified Mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens", J Clin Microbiol, 41(3), pp.948~953 (2003)[DOI]
- Fegou E, "Sensitivity of the Cobas Amplicor system for detection of Mycobacterium tuberculosis in respiratory and extrapulmonary specimens", Clin Microbiol Infect, 11(7), pp.593~596 (2005)[DOI]
- Mitarai S, "Clinical evaluation of Amplicor Mycobacterium detection system for the diagnosis of pulmonary mycobacterial infection using sputum", Tuberculosis, 81(5), pp.319~325 (2001)[DOI]
- 최우순, "호흡기 결핵 환자에서 임상 검사의 유용성", 대한임상검사과학회지, 38(1), pp.54~58 (2006), 대한임상검사과학회
- 조원형, "Comparison of AdvanSure TB", NTM PCR and COBAS TaqMan MTB PCR for Detection of Mycobacterium tuberculosis Complex in Routine Clinical Practice, 2015, pp.35(3), 356~361[DOI]
- Huh HJ, "Comparison of the genedia MTB detection kit and the cobas TaqMan MTB assay for detection of Mycobacterium tuberculosis in respiratory specimens", J Clin Microbiol, 53(3), pp.1012~1014 (2015)[DOI]
- Lee MR, "Evaluation of the Cobas TaqMan MTB real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory specimens", J Med Microbiol, 62(8), pp.1160~1164 (2013)
- Moon JW, "The clinical utility of polymerase chain reaction for the diagnosis of pleural tuberculosis", Clin Infect Dis, 41(5), pp.660~666 (2005)[DOI]
- Lim TK, "Role of clinical judgment in the application of a nucleic acid amplification test for the rapid diagnosis of pulmonary tuberculosis", Chest, 124(3), pp.902~908 (2003)
- Tran AC, "Detection of Mycobacterium avium complex DNA directly in clinical respiratory specimens: opportunities for improved turn-around time and cost savings", Diagn Microbiol Infect Dis, 79(1), pp.43~78 (2014)[DOI]
- Louro AP, "Direct identification of Mycobacterium avium complex and Mycobacterium gordonae from MB", BacT bottles using AccuProbe, 2001, pp.39(2), 570~573
- Lebrun L, "Evaluation of nonradioactive DNA probes for identification of mycobacteria", J Clin Microbiol, 30(9), pp.2476~2478 (1992)
- Makinen J, "Evaluation of a novel strip test, GenoType Mycobacterium CM", AS, for species identification of mycobacterial cultures, 2006, pp.12(5), 481~483
- Richter E, "Evaluation of the GenoType Mycobacterium assay for identification of mycobacterial species from cultures", J Clin Microbiol, 44(5), pp.1769~1775 (2006)[DOI]
- Lee AS, "Identification of non-tuberculous mycobacteria: utility of the GenoType Mycobacterium CM", AS assay compared with HPLC and 16S rRNA gene sequencing, 2009, pp.58(7), 900~904
- Singh AK, "Role of <TEX>$GenoType^{(R)}$<", TEX> common Mycobacteria, J Lab Physicians, pp.2013, 5(2)[DOI]
- Garcia-Agudo L, "Evaluation of INNO-LiPA mycobacteria v2 assay for identification of rapidly growing mycobacteria", Braz J Microbiol, 42(3), pp.1220~1226 (2011)[DOI]
- Padilla E, "Comparative evaluation of the new version of the INNO-LiPA Mycobacteria and genotype Mycobacterium assays for identification of Mycobacterium species from MB", BacT liquid cultures artificially inoculated with Mycobacterial strains, 2004, pp.42(7), 3083~8088
- Trueba F, "Rapid identification of Mycobacterium genavense with a new commercially available molecular test, INNO-LiPA Mycobacteria v2", J Clin Microbiol, 42(9), pp.4403~4404 (2004)[DOI]
- Brosch R, "A new evolutionary scenario for the Mycobacterium tuberculosis complex", Proc Natl Acad Sci USA, 99(6), pp.3684~3689 (2002)[DOI]
- Ueyama M, "Sub-speciation of Mycobacterium tuberculosis complex from tuberculosis patients in Japan", Tuberculosis (Edinb), 94(1), pp.15~19 (2014)[DOI]